At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 23 enrolled
Drug / intervention
Mexiletine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mexiletine for the Treatment of Muscle Cramps in ALS
In Brief
A Phase 4 clinical trial evaluating Mexiletine and Placebo for Muscle Cramps in Amyotrophic Lateral Sclerosis. Completed, enrolled 23 participants across 6 sites.
Detailed Summary
The purpose of this study is to determine if mexiletine is effective for the treatment of muscle cramps in Amyotrophic Lateral Sclerosis (ALS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsUniversity of California, Davis, ALS Association
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartMay 2013
Primary CompletionMar 2016
Study CompletionMay 2016
TodayJul 2026
First PostedMar 14, 2013
Enrollment StartMay 1, 2013
Primary CompletionMar 1, 2016
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.3 years ago
Interventions
Mexiletinedrug
Sodium channel blocker
Placebodrug
Placebo